Zydus, Pharm Aid ink exclusive pact for vaccine technology in Russia

19 Sep 2017 Evaluate

Cadila Healthcare (Zydus Cadila) has entered into an exclusive agreement for the technology know-how for varicella vaccine production in the Russian Federation with Pharm Aid, headquartered in Russia. The exclusive agreement was signed at the BIOTECHMED conference in Gelendzhik, Russia.

The agreement aims to bring in a continuous supply of vaccines which could be included in the critical childhood immunization programme. The demand is estimated at 3 million doses per annum in the Russian Federation alone.

Through this agreement, Zydus gained access to the public and private market segments in the Russian Federation, Belarus, Uzbekistan, Kazakhstan, Armenia and Kyrgyzstan. With an absence of assured supply of indigenously manufactured varicella vaccine, this vaccine does not feature currently in the National Immunisation Programme.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

924.35 0.65 (0.07%)
11-Dec-2025 12:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1799.25
Dr. Reddys Lab 1271.25
Cipla 1507.40
Zydus Lifesciences 924.35
Lupin 2079.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×